Development and validation of a nomogram predicting pathologic complete response to neoadjuvant chemotherapy in luminal type breast cancer patients using MammaPrint® and clinicopathological factor
- 1Department of Surgery, Al Adan Hospital, Hadiya, Ministry of Health, Kuwait
- 2Division of Breast Surgery, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
Abstract
Purpose: Pathological complete response (pCR) of neoadjuvant chemotherapy (NACT) is the most important predictor of successful treatment in locally advanced breast cancer and is associated with survival outcomes. The aim of our study is to investigate a validated nomogram that predicted MammaPrint® to assess the response rate in luminal type breast cancer. Methods: This study retrospectively included patients from Asan Medical Center, Seoul, South Korea who were diagnosed with luminal type breast cancer and received NACT and underwent breast cancer surgery from August 2008 to December 2021. We used a nomogram previously published by colleagues at our center, using a cutoff score of 183. The primary outcome of this study was to investigate the use of nomogram adopted from a 70-gene MammaPrint for prediction of pCR following NACT. Results: Data from 1,574 patients were collected. The nomogram using MammaPrint predicted pCR (odds ratio 2.092, 95% confidence interval 1.507–2.905; p < 0.001). Based on multivariate logistic regression analysis, estrogen receptor status, progesterone receptor status, clinical tumor stage, clinical node stage, and Ki67 index were independent predictive factors of pCR in the primary cohort. The area under the curve of the validated nomogram was 0.64 (95% confidence interval, 0.60–0.67), indicating the nomogram predicted pCR in the neoadjuvant setting. Conclusion: This study provides evidence that the adopted nomogram using the MammaPrint risk assessment based on clinicopathological pre-NACT factors can be utilized in luminal type breast cancer to aid in treatment decisions.
Related
- Incremental Value and Cross-Center Validation of Pretreatment Tri-Modal Ultrasound Deep Learning for Predicting Breast Pathologic Complete Response to Neoadjuvant Chemotherapy: A Multicenter Study
- A Pathological Image-Based Pathomics Signature Combined with Clinicopathological Features for Predicting Lymph Node Metastasis in Esophageal Squamous Cell Carcinoma: A Development and External Validation Study
- A multimodal deep learning radiomics nomogram integrating clinicopathological features for predicting pathological complete response after neoadjuvant therapy in triple-negative breast cancer: a multicenter retrospective study
- Magnetic resonance imaging radiomics for predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer
- Development and internal validation of a clinicopathological and CT radiomics based prediction model for extracranial distant metastasis after radical resection in early-stage non-small cell lung cancer
BibTeX
@article{safi2026development,
title = {{Development and validation of a nomogram predicting pathologic complete response to neoadjuvant chemotherapy in luminal type breast cancer patients using MammaPrint® and clinicopathological factor}},
author = {Sarah Al safi and Tae Kyung Yoo and Jisun Kim and Il Yong Chung and Beom Seok Ko and Hee Jeong Kim and Jong Won Lee and Byung Ho Son and Sae Byul Lee},
journal = {PLOS One},
year = {2026},
month = sep,
doi = {10.1371/journal.pone.0356871},
url = {https://doi.org/10.1371/journal.pone.0356871},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Development and validation of a nomogram predicting pathologic complete response to neoadjuvant chemotherapy in luminal type breast cancer patients using MammaPrint® and clinicopathological factor
AU - Sarah Al safi
AU - Tae Kyung Yoo
AU - Jisun Kim
AU - Il Yong Chung
AU - Beom Seok Ko
AU - Hee Jeong Kim
AU - Jong Won Lee
AU - Byung Ho Son
AU - Sae Byul Lee
PY - 2026
DA - 2026/09/21
JO - PLOS One
DO - 10.1371/journal.pone.0356871
UR - https://doi.org/10.1371/journal.pone.0356871
AB - Purpose: Pathological complete response (pCR) of neoadjuvant chemotherapy (NACT) is the most important predictor of successful treatment in locally advanced breast cancer and is associated with survival outcomes. The aim of our study is to investigate a validated nomogram that predicted MammaPrint® to assess the response rate in luminal type breast cancer. Methods: This study retrospectively included patients from Asan Medical Center, Seoul, South Korea who were diagnosed with luminal type breast cancer and received NACT and underwent breast cancer surgery from August 2008 to December 2021. We used a nomogram previously published by colleagues at our center, using a cutoff score of 183. The primary outcome of this study was to investigate the use of nomogram adopted from a 70-gene MammaPrint for prediction of pCR following NACT. Results: Data from 1,574 patients were collected. The nomogram using MammaPrint predicted pCR (odds ratio 2.092, 95% confidence interval 1.507–2.905; p < 0.001). Based on multivariate logistic regression analysis, estrogen receptor status, progesterone receptor status, clinical tumor stage, clinical node stage, and Ki67 index were independent predictive factors of pCR in the primary cohort. The area under the curve of the validated nomogram was 0.64 (95% confidence interval, 0.60–0.67), indicating the nomogram predicted pCR in the neoadjuvant setting. Conclusion: This study provides evidence that the adopted nomogram using the MammaPrint risk assessment based on clinicopathological pre-NACT factors can be utilized in luminal type breast cancer to aid in treatment decisions.
SN - 1932-6203
ER -